focus -WSS

focus

author：hotspot 2025-09-28 20:44:41 - browse：732

Doctor sitting at a crowded desk. -- first opinion coverage from STAT — Adobe

SAN FRANCISCO — If you learned anything about nonprofit hospitals on the first day of the J.P. Morgan Healthcare Conference, it’s that they’ve all but abandoned the prospect of making significant profit on patient care. Instead, they’re fully throwing their weight into other ways of making money — things like developing drugs or selling insurance.

Making money outside of patient care — or “revenue diversification,” if you prefer industry jargon — has always made appearances on hospital slides at the annual investor conference in San Francisco. This year, though, hospital executives are projecting a sense of urgency around growing profit in other areas to make up for losing money on their bread and butter: taking care of patients in hospitals.

“It used to be nice to have, but now it’s a must-have, especially for not-for-profit health systems,” Niyum Gandhi, the chief financial officer of Boston’s Mass General Brigham said in an interview with STAT after his presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： The Readout: Lenmeldy, GLP

WSS

Merck drug for rare lung condition set for approval in U.S.

Biogen Alzheimer’s drug launch off to slow start

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

BioAge raises $170M for combination therapy with Zepbound

Private equity deals in Medicare Advantage declines

Key House Republican on health care plans exit from Congress

entertainment

focus

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Gilead might be held responsible for not developing a drug

Hepatitis C has a cure — but many Americans still lack access to it

What should King Charles tell the public about his cancer?

The high cost of giving birth even with insurance

Abortion pill case raises question: who can sue the FDA?

In age of alternative facts, a scholarly course on calling out crap

Biogen Alzheimer’s drug launch off to slow start

DIEP, the 'gold standard' of breast reconstruction, is under threat

Key House Republican on health care plans exit from Congress

focus

What we’ve learned from the Aduhelm mess

Why did Pfizer dish out millions for a Super Bowl ad?

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Gilead might be held responsible for not developing a drug

Oprah kicked off a national conversation on obesity. Let's have it

leisure time

leisure time

Wikipedia

Wikipedia